About Cascadian Therapeutics (NASDAQ:CASC)
Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:CASC
CUSIP68232410
Phone+1-206-8012100
Debt
Debt-to-Equity RatioN/A
Current Ratio8.07%
Quick Ratio8.07%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.16 per share
Price / Book4.62
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-56,930,000.00
Net MarginsN/A
Return on Equity-43.53%
Return on Assets-40.90%
Miscellaneous
Employees57
Outstanding Shares50,620,000
Cascadian Therapeutics (NASDAQ:CASC) Frequently Asked Questions
What is Cascadian Therapeutics' stock symbol?
Cascadian Therapeutics trades on the NASDAQ under the ticker symbol "CASC."
How were Cascadian Therapeutics' earnings last quarter?
Cascadian Therapeutics Inc (NASDAQ:CASC) issued its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. During the same quarter in the prior year, the company posted ($0.09) earnings per share. View Cascadian Therapeutics' Earnings History.
What price target have analysts set for CASC?
4 analysts have issued twelve-month target prices for Cascadian Therapeutics' stock. Their forecasts range from $4.00 to $10.00. On average, they expect Cascadian Therapeutics' share price to reach $7.00 in the next twelve months. View Analyst Ratings for Cascadian Therapeutics.
What are Wall Street analysts saying about Cascadian Therapeutics stock?
Here are some recent quotes from research analysts about Cascadian Therapeutics stock:
- 1. According to Zacks Investment Research, "Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company's product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. " (1/9/2018)
- 2. Cantor Fitzgerald analysts commented, "Pooled analysis from Phase Ib trial in HER2+ metastatic breast cancer patients with or without brain metastases demonstrated similarity in PFS between two groups (264P), which is a secondary endpoint in the HER2CLIMB trial." (9/11/2017)
- 3. Cowen Inc analysts commented, "CASC reported 1Q financials and provided a pipeline update." (5/9/2017)
Who are some of Cascadian Therapeutics' key competitors?
Some companies that are related to Cascadian Therapeutics include Live Oak Bank (LOB), Providence Service (PRSC), Boingo Wireless (WIFI), Hanmi Financial (HAFC), U.S. Concrete (USCR), Sunrun (RUN), MacroGenics (MGNX), Sonic Drive-In (SONC), Radware (RDWR), Given Imaging (GIVN), Access Pharmaceuticals (ABEO), Perfect World (PWRD), Luminex (LMNX), Monotype Imaging (TYPE), CommerceHub (CHUBA), CommerceHub (CHUBK), CareTrust REIT (CTRE) and LivePerson (LPSN).
Who are Cascadian Therapeutics' key executives?
Cascadian Therapeutics' management team includes the folowing people:
- Christopher S. Henney Ph.D., Chairman of the Board (Age 76)
- Scott D. Myers, President, Chief Executive Officer, Director (Age 51)
- Julia Marie Eastland, Chief Financial Officer, Vice President - Corporate Development, Secretary (Age 51)
- Gary W. Christianson, Chief Operating Officer (Age 61)
- Scott Peterson Ph.D., Chief Scientific Officer (Age 54)
- Robert W. Azelby, Director (Age 49)
- Gwendolyn A. Fyfe M.D., Independent Director (Age 65)
- Steven P. James, Independent Director (Age 58)
- Ted W. Love M.D., Independent Director (Age 58)
- Daniel Keith Spiegelman, Independent Director (Age 58)
Has Cascadian Therapeutics been receiving favorable news coverage?
News articles about CASC stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cascadian Therapeutics earned a media sentiment score of 0.16 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 44.54 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Cascadian Therapeutics?
Shares of CASC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cascadian Therapeutics' stock price today?
One share of CASC stock can currently be purchased for approximately $9.98.
How big of a company is Cascadian Therapeutics?
Cascadian Therapeutics has a market capitalization of $506.61 million. Cascadian Therapeutics employs 57 workers across the globe.
How can I contact Cascadian Therapeutics?
Cascadian Therapeutics' mailing address is 3101 Western Ave Ste 600, SEATTLE, WA 98121-3047, United States. The biopharmaceutical company can be reached via phone at +1-206-8012100 or via email at [email protected]
MarketBeat Community Rating for Cascadian Therapeutics (CASC)
MarketBeat's community ratings are surveys of what our community members think about Cascadian Therapeutics and other stocks. Vote "Outperform" if you believe CASC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cascadian Therapeutics (NASDAQ:CASC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Cascadian Therapeutics in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible downside of 29.86%. The high price target for CASC is $10.00 and the low price target for CASC is $4.00. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.20 | 2.40 | 2.40 |
| Ratings Breakdown: | 1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.00 | $7.00 | $6.00 | $6.00 |
| Price Target Upside: | 29.86% downside | 29.86% downside | 67.13% upside | 67.13% upside |
Cascadian Therapeutics (NASDAQ:CASC) Consensus Price Target History
Cascadian Therapeutics (NASDAQ:CASC) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Cascadian Therapeutics (NASDAQ:CASC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cascadian Therapeutics (NASDAQ CASC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 81.38%
Cascadian Therapeutics (NASDAQ CASC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/11/2017 | Scott Dunseth Myers | Insider | Buy | 5,500 | $3.74 | $20,570.00 | 49,716 |  |
| 5/12/2017 | Scott Dunseth Myers | Insider | Buy | 2,800 | $4.00 | $11,200.00 | 44,216 | |
| 3/31/2017 | Scott Dunseth Myers | Insider | Buy | 2,000 | $4.11 | $8,220.00 | 41,416 | |
| 3/28/2017 | Gwen A Fyfe | Director | Buy | 1,666 | $4.12 | $6,863.92 | 3,332 | |
| 3/20/2017 | Scott Dunseth Myers | Insider | Buy | 1,000 | $3.93 | $3,930.00 | 39,416 | |
| 2/2/2017 | Ted W. Love | Director | Buy | 23,000 | $4.24 | $97,520.00 | | |
| 1/30/2017 | Christopher S Henney | Director | Buy | 25,324 | $4.11 | $104,081.64 | 50,000 | |
| 1/27/2017 | Scott Dunseth Myers | Insider | Buy | 20,500 | $3.76 | $77,080.00 | | |
| 8/17/2016 | Scott Dunseth Myers | Insider | Buy | 45,000 | $1.15 | $51,750.00 | 107,500 | |
| 6/28/2016 | Scott Dunseth Myers | CEO | Buy | 62,500 | $0.80 | $50,000.00 | 62,500 | |
| 6/1/2015 | Diana Hausman | Insider | Buy | 5,747 | $4.65 | $26,723.55 | | |
| 3/26/2015 | Daniel K Spiegelman | Director | Buy | 10,000 | $1.59 | $15,900.00 | | |
| 3/25/2015 | Daniel K Spiegelman | Director | Buy | 10,000 | $1.63 | $16,300.00 | | |
| 12/17/2014 | Bvf Partners L P/Il | Major Shareholder | Buy | 378,444 | $1.82 | $688,768.08 | | |
| 12/15/2014 | Bvf Partners L P/Il | Major Shareholder | Buy | 224,949 | $1.88 | $422,904.12 | | |
| 9/23/2014 | Jay Venkatesan | EVP | Buy | 250,000 | $2.00 | $500,000.00 | | |
| 7/10/2014 | Daniel K Spiegelman | Director | Sell | 3,403 | $1.72 | $5,853.16 | | |
| 2/20/2014 | Daniel K Spiegelman | Director | Sell | 12,780 | $1.96 | $25,048.80 | | |
| 11/1/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 129,000 | $1.78 | $229,620.00 | | |
| 8/8/2013 | Bvf Partners P/Il | major shareholder | Buy | 258,361 | $1.65 | $426,295.65 | | |
| 8/1/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 338,087 | $1.74 | $588,271.38 | | |
| 6/7/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 214,467 | $1.81 | $388,185.27 | | |
| 12/27/2012 | Wendy W Warren | Major Shareholder | Sell | 57,943 | $64.30 | $3,725,734.90 | | |
(Data available from 1/1/2013 forward)
Cascadian Therapeutics (NASDAQ CASC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Cascadian Therapeutics (CASC) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - April 11 at 12:43 AM |
| Cascadian Therapeutics Inc (CASC) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 1 at 3:24 AM |
| Cascadian Therapeutics (CASC) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 26 at 10:06 AM |
| Cascadian Therapeutics (CASC) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 26 at 9:13 AM |
| Ignyta (RXDX) versus Cascadian Therapeutics (CASC) Head-To-Head Review
www.americanbankingnews.com - March 26 at 7:35 AM |
 | Form SC 13D/A Cascadian Therapeutics, Filed by: Growth Equity Opportunities IV, LLC - StreetInsider.com
www.streetinsider.com - March 19 at 4:23 PM |
| Cascadian Therapeutics Inc (CASC) Short Interest Update
www.americanbankingnews.com - March 14 at 1:38 AM |
| Form 4 Cascadian Therapeutics, For: Mar 09 Filed by: PETERSON SCOTT ROBERT - StreetInsider.com
www.streetinsider.com - March 13 at 6:22 PM |
| Cascadian Therapeutics (CASC) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 11 at 6:31 PM |
| Cantor Fitzgerald Analysts Give Cascadian Therapeutics (CASC) a $10.00 Price Target
www.americanbankingnews.com - March 9 at 7:30 PM |
| Seattle Genetics (SGEN) Completes Acquisition of Cascadian Therapeutics (CASC)
www.streetinsider.com - March 9 at 5:30 PM |
 | Seattle Genetics Completes Acquisition of Cascadian Therapeutics
finance.yahoo.com - March 9 at 9:58 AM |
| Cascadian Therapeutics Inc (CASC) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 7 at 3:44 AM |
| Cascadian Therapeutics Inc (CASC) Sees Large Growth in Short Interest
www.americanbankingnews.com - March 3 at 3:26 AM |
| -$0.29 Earnings Per Share Expected for Cascadian Therapeutics Inc (CASC) This Quarter
www.americanbankingnews.com - March 2 at 12:22 PM |
| Analysts Expect Cascadian Therapeutics Inc (CASC) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - February 13 at 3:18 PM |
| Cascadian Therapeutics Inc (CASC) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 10 at 3:24 AM |
| Analyzing Cascadian Therapeutics (CASC) and Uniqure (QURE)
www.americanbankingnews.com - February 9 at 10:12 AM |
| Seattle Genetics (SGEN) Commences Tender Offer for Cascadian Therapeutics (CASC)
www.streetinsider.com - February 9 at 9:14 AM |
| ACT NOW: Monteverde & Associates PC Announces An Investigation of Cascadian Therapeutics, Inc. - CASC
finance.yahoo.com - February 9 at 9:14 AM |
| Today’s Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Cascadian Therapeutics
finance.yahoo.com - February 9 at 9:13 AM |
| Today’s Research Reports on Trending Tickers: Cascadian Therapeutics and UnitedHealth Group
finance.yahoo.com - February 8 at 8:54 AM |
| SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Cascadian Therapeutics, Inc. - CASC
finance.yahoo.com - February 7 at 9:14 AM |
 | What Seattle Genetics' Surprise Acquisition Means For The Bottom Line - Seeking Alpha
seekingalpha.com - February 4 at 9:08 AM |
| Investors Buy Large Volume of Cascadian Therapeutics Call Options (CASC)
www.americanbankingnews.com - February 4 at 1:06 AM |
| Wired News – Seattle Genetics to Acquire Cascadian Therapeutics
finance.yahoo.com - February 2 at 9:11 AM |
| Cascadian Therapeutics Target of Unusually Large Options Trading (CASC)
www.americanbankingnews.com - February 2 at 1:16 AM |
 | Cascadian Therapeutics (CASC) Earnings Growth Limit Rating
investorplace.com - February 1 at 10:12 AM |
| CASCADIAN THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
finance.yahoo.com - February 1 at 9:15 AM |
| Cascadian Therapeutics Scores Big On Seattle Genetics Acquisition
finance.yahoo.com - February 1 at 9:15 AM |
| Raymond James Financial Lowers Cascadian Therapeutics (CASC) to Market Perform
www.americanbankingnews.com - January 31 at 5:34 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Cascadian Therapeutics, Inc. to Seattle Genetics, Inc. for $10.00 Per Share is Fair to Shareholders
finance.yahoo.com - January 31 at 4:26 PM |
 | BRIEF-Seattle Genetics Says If Deal Terminated Under, Cascadian Therapeutics To Pay Fee Of $17 Million
www.reuters.com - January 31 at 9:25 AM |
 | Seattle Genetics To Buy Cascadian Therapeutics; Sees Higher Q4 Revenues
www.nasdaq.com - January 31 at 9:25 AM |
 | Cascadian's stock rockets to pace premarket gainers after Seattle Genetics buyout deal
www.marketwatch.com - January 31 at 9:25 AM |
| Cascadian (CASC) Alert: Johnson Fistel Investigates Proposed Sale of Cascadian Therapeutics, Inc.; Is $10.00 a Fair Price for Shareholders?
finance.yahoo.com - January 31 at 9:25 AM |
| Cascadian Therapeutics Inc (CASC) Short Interest Down 36.2% in January
www.americanbankingnews.com - January 29 at 1:20 AM |
| Critical Comparison: Cascadian Therapeutics (CASC) versus Regenxbio (RGNX)
www.americanbankingnews.com - January 28 at 5:18 AM |
| Analysts Expect Cascadian Therapeutics Inc (CASC) to Announce -$0.29 Earnings Per Share
www.americanbankingnews.com - January 27 at 5:20 PM |
| Cascadian Therapeutics Inc (CASC) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 16 at 3:38 AM |
| Zacks: Brokerages Anticipate Cascadian Therapeutics Inc (CASC) to Post -$0.29 Earnings Per Share
www.americanbankingnews.com - January 10 at 5:30 PM |
| Cascadian Therapeutics (CASC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 9 at 8:12 PM |
| Cascadian Therapeutics (CASC) Announces 2018 Outlook
www.streetinsider.com - January 4 at 5:12 PM |
| Cascadian Therapeutics Announces 2018 Outlook and Recent Progress
finance.yahoo.com - January 4 at 9:36 AM |
 | Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference
www.prnewswire.com - January 2 at 6:29 PM |
| BRIEF-Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From The European Medicines Agency
www.reuters.com - January 2 at 6:29 PM |
 | Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency - GlobeNewswire (press release)
globenewswire.com - January 2 at 9:35 AM |
| Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
finance.yahoo.com - January 2 at 9:35 AM |
| BRIEF-Cascadian Therapeutics Files For Mixed Shelf Of Up To $250 Mln
www.reuters.com - December 29 at 5:08 PM |
| -$0.29 EPS Expected for Cascadian Therapeutics Inc (CASC) This Quarter
www.americanbankingnews.com - December 25 at 3:26 AM |
Cascadian Therapeutics (NASDAQ:CASC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cascadian Therapeutics (NASDAQ:CASC) Income Statement, Balance Sheet and Cash Flow Statement
Cascadian Therapeutics (NASDAQ CASC) Stock Chart for Monday, April, 23, 2018
Loading chart…
